PPARG and metabolic dysfunction-associated steatotic liver disease: ,467 Paradoxically, pharmacological activation of PPARγ improves features of MASLD, including hepatic steatosis, ballooning, and inflammation, and also the stage of fibrosis in non-diabetic, prediabetic, and T2D patients with MASLD.468